Physician profile
Sina Vahedi
NPI 1679005219
$2,413.21
in general payments reported to CMS, 2019-2025
14 companies · $144 in 2025
The $144 reported for 2025 was less than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $29.93 · 2021: $90.97 · 2022: $440 · 2023: $1,206 · 2024: $279 · 2025: $144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $893 · Food and Beverage: $736.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $892.87 |
| Food and Beverage | $736.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,325.06 | 2022-2024 | Durysta, Lumigan, Xen Glaucoma Treatment System |
| Alcon Vision LLC | $335.20 | 2019-2025 | Hydrus Microstent |
| Sight Sciences, INC. | $131.58 | 2024 | Omni Surgical System |
| Mallinckrodt Enterprises LLC | $118.75 | 2019 | |
| Sun Pharmaceutical Industries INC. | $108.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $81.00 | 2019 | |
| Glaukos Corporation | $71.44 | 2023 | Istent Infinite Trabecular Micro-Bypass System Model Is3, Is3-Istent Infinitetrabecular Micro-Bypass System Model Is3 |
| Novartis Pharmaceuticals Corporation | $62.14 | 2022 | |
| Bausch & Lomb Americas INC. | $59.48 | 2022 | |
| Eyevance Pharmaceuticals LLC | $37.41 | 2021-2022 | |
| Horizon Therapeutics Plc | $26.25 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $21.74 | 2021 | |
| Allergan, INC. | $17.60 | 2022 | |
| Dompe US, INC. | $16.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sina Vahedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.